Mast cell activation syndrome: Importance of consensus criteria and call for research

Peter Valent, MD\textsuperscript{a}, Cem Akin, MD, PhD\textsuperscript{b}, Patrizia Bonadonna, MD\textsuperscript{c}, Karin Hartmann, MD\textsuperscript{d}, Sigurd Broesby-Olsen, MD\textsuperscript{e}, Knut Brockow, MD\textsuperscript{f}, Joseph H. Butterfield, MD\textsuperscript{g}, Andreas Reiter, MD\textsuperscript{h}, Jason Gottlib, MD\textsuperscript{i}, Mariana Castells, MD, PhD\textsuperscript{j}, Joshua D. Milner, MD\textsuperscript{k}, Melody C. Carter, MD\textsuperscript{l}, Hirsh Komarow, MD\textsuperscript{m}, Deepti Radia, MD\textsuperscript{n}, Animesh Pardanani, MBBS, PhD\textsuperscript{o}, Karl Sotlar, MD\textsuperscript{p}, Massimo Triggiani, MD, PhD\textsuperscript{q}, Hans-Peter Horny, MD\textsuperscript{p}, Michel Arock, PharmD, PhD\textsuperscript{q}, Lawrence B. Schwartz, MD, PhD\textsuperscript{r}, Dean D. Metcalfe, MD\textsuperscript{r}

\textsuperscript{a}Department of Internal Medicine I, Division of Haematology, Medical University of Vienna, Vienna, Austria

\textsuperscript{b}Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich

\textsuperscript{c}Allergy Unit, Verona University Hospital, Verona, Italy

\textsuperscript{d}Department of Dermatology, University of Luebeck, Luebeck, Germany

\textsuperscript{e}Department of Dermatology and Allergy Centre Odense University Hospital, Odense, Denmark

\textsuperscript{f}Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany

\textsuperscript{g}Division of Allergic Diseases, Mayo Clinic, Rochester, Minn

\textsuperscript{h}III Medizinische Klinik, Universitäts-Medizin Mannheim, Universität Heidelberg, Mannheim, Germany

\textsuperscript{i}Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif

\textsuperscript{j}Division of Allergy and Immunology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass

\textsuperscript{k}Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md

\textsuperscript{l}Department of Haematology, Guys and St Thomas’ NHS Foundation Trust, Guys Hospital, London, United Kingdom

\textsuperscript{m}Division of Hematology, Mayo Clinic, Rochester, Minn

\textsuperscript{n}Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria

\textsuperscript{o}Division of Allergy and Clinical Immunology University of Salerno, Salerno, Italy

Disclosure of potential conflict of interest: The authors declare that they have the following conflict of interest in this study: Virginia Commonwealth University receives royalties from Thermo Fisher for the tryptase assay, which are then shared with LBS, its inventor. The authors declare that they have no additional conflicts of interest to disclose in this project.
To the Editor:

Mast cell activation syndrome (MCAS), as defined by existing consensus criteria, is a condition characterized by mediator-related symptoms associated with a substantial systemic activation of mast cells (MCs).\textsuperscript{1,2} Referrals to centers with experience in treatment of MC disorders of patients with a diagnosis of MCAS have increased dramatically recently. The patients referred often do not meet the definition of MCAS and have often undergone extensive evaluations. Referral centers frequently find that in the face of these extensive prior evaluations and in the absence of evidence that MCs are involved, they have little to offer. This letter is written to summarize this situation and propose a way forward.

Originally and to develop a uniform and thoughtful basis for the clinical study and diagnosis of MCAS, a consensus group consisting of an international panel of allergy, hematology, pathology, and dermatology specialists met and introduced the diagnostic criteria for MCAS based on the logic that if MCs are responsible, then clinical data must support the involvement of the MC compartment.\textsuperscript{1,2} The consensus group set forth criteria for the diagnosis of MCAS as follows.

The first criterion is the episodic occurrence of typical MC-related clinical symptoms, such as urticaria, angioedema, flushing, pruritus, nausea, hoarseness, vomiting, diarrhea, abdominal cramping, hypotensive syncope, tachycardia, wheezing, conjunctival injection, nasal congestion, and headache. To meet this first diagnostic criterion, the episodic occurrence of such symptoms affecting 2 or more organ systems should be observed.\textsuperscript{1,2}

The second criterion is an increase in serum tryptase level by 20% over the individual baseline plus 2 ng/mL total (eg, from 10 ng/mL to ≥14 ng/mL or from 30 ng/mL to ≥38 ng/mL) within a 4-hour window after the reaction.

The third criterion is a clear response (improvement) of the symptoms to drugs targeting MC-derived mediators, MC-stabilizing agents, or both.\textsuperscript{2}

When these criteria are met in patients with systemic mastocytosis, by consensus, MCAS is referred to as primary or clonal MCAS. MCAS is also observed in patients with evidence of clonal MCs not fulfilling the criteria of mastocytosis.\textsuperscript{3,4} When fulfilled in patients with IgE-dependent allergic reactions or other reactive processes, the term applied is secondary MCAS (Table I).\textsuperscript{1,2} When no underlying cause is identified, the diagnosis is idiopathic MCAS.\textsuperscript{2} MCAS criteria are accepted widely and have been validated in specific situations.\textsuperscript{5}

The diagnosis of MCAS is being applied currently to patients with unresolved complex medical problems after extensive medical evaluations, and a substantial number of these patients do not meet the diagnostic criteria for MCAS. Once the referral center providers...
eliminate diseases in the differential diagnosis, they find they have little to add in the way of providing a satisfactory response or therapy because no MCAS is found. In other cases an underlying disease unrelated to MCAS is (later) detected, and an unnecessary delay of such a diagnosis might be a consequence of the MCAS referral.

Finally, the suggestion to patients that they have an MC disorder beyond (or in addition to) MCAS is not without consequences. Suggestion of an MC disorder can lead to unjustified anxiety and fear for patients, especially when the concept of MCAS is understood as synonymous to systemic mastocytosis, which can lead to hematologic malignancy. Moreover, in those without typical clinical symptoms, there can be increased costs and health care use in an effort to implicate MCs in pathology.

Is it possible that there are MC diseases outside of what we currently understand? Certainly this possibility exists. There are patients with chronic symptoms that do not appear to flare in the classical sense. One example is hereditary (familial) tryptasemia, in which tryptase levels are consistently elevated and in which many patients complain of nonepisodic itch, hives, and abdominal pain. This more recent discovery raises the possibility that there might be patients for whom levels of other mediators are increased chronically and other cell types additionally involved, either locally or systemically. Another such example is an increased tryptase level in patients with a myeloid or eosinophil neoplasms who might have clonal MCs and similar symptoms, including pruritus, abdominal pain, and skin rashes.

We suggest that the solution to this emerging problem is 4-fold. First, caution is needed in applying the diagnosis of MCAS, and consensus criteria should be met. MCAS should not be applied on the basis of a persistently elevated basal serum tryptase level and not based on the fact that the condition has resisted previous attempts to establish a medical diagnosis.

Second, if the diagnosis is applied, referral centers must be prepared to evaluate these patients and eliminate diseases in the differential diagnosis. It is important to recognize that other pathologic conditions, including sepsis, cytokine storm associated with administration of biologics, acute intoxication, poisoning, and endocrinology emergencies can mimic MCAS. And in those with increased basal tryptase levels, diverse hematologic neoplasms, chronic inflammation, or familial tryptasemia may be detected.

Third, referral centers must implement a follow-up plan for monitoring and care of these patients and/or until a research protocol is in place to understand the difficulties that lead to this diagnosis.

Fourth, clinical research programs are needed to explore the possibility that there are yet to be defined MC activation disorders. Such studies need to evaluate the consensus criteria for MCAS. Strategies need to be in place to identify specific phenotypes/endotypes with underlying genetic variants that will lead to uniform diagnostic approaches. Interventional trials with agents known to decrease MC numbers or MC mediator release and the downstream actions of these mediators are needed. Subjects for discussion include consideration of the possibility that there are chronic and local forms of MC activation not fulfilling MCAS criteria in which patients present with multiple symptoms and how to document such a possibility. Are there unrecognized MC diseases that involve tissue-specific
or regional MC activation? Are there additional clinically useful markers of MC activation, and how can these conditions be defined?

Currently, only a few biomarkers are recognized as implicating MC activation in pathology. One example is histamine or its metabolites when measured in urine, although histamine is produced by MCs and basophils. Measurement of tryptase levels in bodily fluids is more specific and generally considered the most reliable diagnostic test of MC involvement and thus strongly recommended within consensus diagnostic criteria. Prostaglandin D<sub>2</sub> and histamine metabolite levels in urine can both increase over baseline values in patients with MCAS and have also been measured and used as a guide for treatment, although their increase might not always be associated with MC activation. Chromogranin A is not produced by MCs in patients with mastocytosis and thus is not a reasonable marker of MC activation. Similarly, plasma levels of heparin have not been demonstrated generally to be a sensitive or specific biomarker for MC activation, although this requires further study.

With the goal of alleviating patients’ suffering, a balanced approach is thus clearly warranted to both deal with current issues surrounding patients with suspected MC disorders and to promote well-designed and thoughtful prospective clinical research protocols to answer these critical questions.

**Acknowledgments**

Supported in part by the Austrian Science Funds (FWF) projects F4701-B20 and F4704-B20 and by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

**References**

Table 1

Estimated percentage of patients with a specific disorder (underlying condition) who experience events that meet the diagnostic criteria of MCAS*

<table>
<thead>
<tr>
<th>Disorder/underlying condition</th>
<th>Estimated percentage of those with events meeting the definition of MCAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td>10</td>
</tr>
<tr>
<td>SM</td>
<td>10-20</td>
</tr>
<tr>
<td>KIT D816V+ MCs without CM or SM</td>
<td>Unknown</td>
</tr>
<tr>
<td>CM or SM with concomitant allergy</td>
<td>30-50</td>
</tr>
<tr>
<td>IgE-dependent allergy</td>
<td>10-20</td>
</tr>
<tr>
<td>IgE-independent allergy</td>
<td>Unknown</td>
</tr>
<tr>
<td>Acute drug hypersensitivity reactions</td>
<td>10-20</td>
</tr>
<tr>
<td>Intoxications†</td>
<td>1-3</td>
</tr>
<tr>
<td>Acute infections</td>
<td>1-3</td>
</tr>
<tr>
<td>Acute autoimmune disease episode</td>
<td>1-3</td>
</tr>
<tr>
<td>Sickle cell disease, acute episode</td>
<td>1-3</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Clonal myeloid neoplasms/leukemia</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Clonal lymphatic neoplasms/leukemia</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Neurologic disorders‡</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Hereditary metabolic disorders</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Ehlers-Danlos syndrome</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>

CM, Cutaneous mastocytosis; SM, systemic mastocytosis.

*MCAS is based on MCAS criteria, as defined by Valent et al.2 The frequency of MCAS was estimated on the basis of published results, and data are presented in conferences in the years 2010-2018. Experience might differ substantially depending on the referral center.

†Food intoxication resulting from high histamine content (eg, scombroid fish poisoning) can mimic MCAS unless pre-event and postevent tryptase levels were measured.

‡Including autonomic dysfunction, such as postural tachycardia syndrome and gastrointestinal motility disorders.